Children's health is a key concern in China at present. The incidence rate of precocious puberty in China is 2%, which is an important disease threatening children's physical and mental health. Idiopathic central precocious puberty (ICPP) is the most common type. This article reviews the current clinical research status, latest achievements, and cutting-edge trends of ICPP. The latest“Expert Consensus on Diagnosis and Treatment of Central Sexual Precocity (2022)”up-dates the age limit of central sexual precocity from 8 to 7.5 years old. Gene diagnosis is a new method to assist in the diagnosis of ICPP, and the“2022 Consensus”suggests that children with the family history of precocious puberty should undergo gene testing. GnRH agonists (GnRHa) are the gold standard treatment regimen for ICPP, which are beneficial for inhibiting bone age development, increasing the final adult height of children, reducing body mass index, and improving brain function. The traditional Chinese medicine treatment of ICPP is currently a research hotspot, including traditional Chinese medicine internal treatment, as well as external treatment methods such as ear acupoint pressing and massage, it has a significant therapeutic effect on ICPP, with its efficacy superior to GnRHa, and its safety may be better. Traditional Chinese medicine or a combination of traditional Chinese and Western medicine is expected to become a cutting-edge treatment option for ICPP.

child health  /  idiopathic central precocious puberty  /  gene diagnosis  /  GnRH agonists  /  Traditional Chinese medicine treatment  /  integrated Traditional Chinese and Western Medicine